Bitcoin sets a new all-time high above $6,000 >>> READ MORE

Bull’s Eye Report: Gilead Sciences (GILD)

GILD looks the best in the biotech space today


At, we strive to “own the best and ignore the rest” in our equity portfolios. Toward this end, each day we search our database for a “top stock” (a top rated company in terms of earnings strength as well as company and industry performance) that presents a strong technical “set up” and a good entry point.

In short, when our equity team is looking to add a stock to one of our portfolios, the “bull’s eye” stock shown below is generally their first choice.

Company Symbol Industry Stock Rating YTD% Gain S.T. Stop Loss
Gilead Sciences GILD Biotechnology 9.8 +59.96% $55.97

Why We Like The Stock:

Gilead Sciences (GILD) is our most compelling buy today due to the fact that it is a top rated stock (in terms of earnings strength and company/industry performance) with a positive technical set-up. Biotech stocks are tough to pin, as they tend not to move together. Compare Pfizer (PFE), GlaxoSmithKline (GSK), Valeant Pharmaceuticals (VRX), and the SPDR Biotech ETF (XBI) — not exactly similar. So, when looking at biotech stocks, we like to analyze picks on an individual trade basis.

GILD features a fantastic daily chart, though the weekly trend (nearly parabolic) is concerning. However, the stock recently hit highs of $64.04 on July 26, so there is still some decent immediate upside in a short-term trade. We would be buyers of GILD here or on a pullback to the 50-day moving average, as long as it stays above its August 15 intraday low. We expect a run back to July highs.

We Would Be Buyers:

At the current price (~$59.70), or on a pullback to the 50-day moving average ($57.01).

Company Profile:

Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead’s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company’s products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.

Stock Rating: 9.8

The Stock Rating indicates the combined score of our proprietary Earning Strength and Company Performance models. The rating scale is 0 – 10 with 10 being the highest.

Gilead Sciences – Last Three Months


Gilead Sciences – Last 12 Months


Gilead Sciences – Last Five Years

Looking to trade the Bull’s Eye stock picks? Click here to download our free Special Report, “How We Identify Our “Bull’s Eye” Picks & How You Can Profit Trading Them”

At the time of publication the editor and affiliated companies own the following positions: GILD

Note: Positions may be bought or sold while this publication is in circulation without notice.

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC